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Background: There is no information on the effects of the breed, gender and age on the cellular content and
growth factor (GF) release from equine pure-platelet rich plasma (P-PRP) and pure-platelet rich gel (P-PRG). The
objectives of this study were: 1) to compare the cellular composition of P-PRP with whole blood and platelet poor
plasma (PPP); 2) to compare the concentration of transforming GF beta 1 (TGF-β1) and platelet derived GF isoform
BB (PDGF-BB) between P-PRP treated with non-ionic detergent (P-PRP+NID), P-PRG (activated with calcium
gluconate -CG-), PPP+NID, PPP gel (PPG), and plasma and; 3) to evaluate and to correlate the effect of the breed,
gender and age on the cellular and GF concentration for each blood component. Forty adult horses, 20
Argentinean Creole Horses (ACH) and, 20 Colombian Creole Horses (CCH) were included. Data were analyzed by
parametric (i.e.: t-test, one way ANOVA) and non parametric (Kruskal-Wallis test, Wilcoxon test) tests. Correlation
analysis was also performed by using the Spearman and Pearson tests. A p≤ 0.05 was set as significant for all tests.
All the blood components were compared for platelet (PLT), leukocyte (WBC), TGF-β1 and PDGF-BB concentrations.
The effect of the breed, gender and age on these variables was analyzed. A P≤ 0.05 was accepted as significant for
all the tests.
Results: PLT counts were 1.8 and 0.6 times higher in P-PRP than in whole blood and PPP, respectively; WBC counts
were 0.5 and 0.1 times lower in P-PRP, in comparison with whole blood and PPP, respectively. TGF-β1 and PDGF-BB
concentrations were 2.3 and 262 times higher, respectively, in P-PRG than in plasma, and 0.59 and 0.48 times
higher, respectively, in P-PRG than in PPG. P-PRG derived from CCH females or young horses presented significantly
(P < 0.001) higher PDGF-BB concentrations than P-PRG derived from ACH males or older horses.
Conclusions: Our results indicated that P-PRP obtained by a manual method was affected by intrinsic factors such
as the breed, gender and age. Equine practitioners should be aware that cellular and GF release from P-PRP/P-PRG
could change according with the intrinsic variables associated with a patient in particular.
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The clinical use of platelet concentrates (PC) is currently
a common biological therapy for musculoskeletal diseases
[1-4] and wounds in horses [5]. PC intended for regenera-
tive medicine are classified as: pure-platelet rich plasma
(P-PRP), leukocyte-platelet rich plasma (L-PRP) and plate-
let rich fibrin (PRF). P-PRP and L-PRP are obtained in a* Correspondence: carmona@ucaldas.edu.co
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reproduction in any medium, provided the orliquid form by using anticoagulants. PRF is as a second
generation PC that does not require anticoagulant for its
elaboration [6].
Equine P-PRP displays slightly higher platelet counts
(1.3-4 fold) and leukocyte (WBC) counts (0.5-2 fold)
than whole blood. Equine L-PRP has increased platelet
(5 fold) and leukocyte (3 fold or more) counts when
compared to whole blood. When PC are activated by
adding thrombin or a calcium salt, they form a fibrin
polymer and are known as platelet gels (PG). Thus, PG
from P-PRP is denominated as pure-platelet rich gelLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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platelet rich gel (L-PRG) [7].
Platelet gels release several growth factors (GF), such
as transforming growth factor beta 1 (TGF-β1) [8,9]
and platelet derived growth factor type BB (PDGF-BB)
[10]. These proteins have anti-inflammatory, anabolic
and angiogenic effects [11]. Both GF are mainly stored
in platelet alpha granules and their release correlates
with the degree of platelet activation. The GF profile
released from P-PRP or L-PRP will be determined by
the cellular components concentrated in each sub-
stance [12].
Many questions emerge when a particular PC (either
P-PRP or L-PRP) is proposed for regenerative therapy
in horses. First, it is essential to know the cellular and
GF profile of this substance before its (experimental
or clinical) use. Several intrinsic and extrinsic aspects
could influence the cellular and molecular features
of a PC. Intrinsic factors such as breed, gender and,
age or, extrinsic factors associated to the technique
used for the PC preparation and activation could po-
tentially influence on the final composition of these
substances.
This study evaluates the effect of intrinsic factors such
as, the breed, gender and age on the cellular characteris-
tics and release of TGF-β1 and PDGF-BB from equine
P-PRP/P-PRG. The objectives of this study were: 1) to
compare the cellular composition of P-PRP with whole
blood and platelet poor plasma (PPP); 2) to compare the
concentration of transforming GF beta 1 (TGF-β1) and
platelet derived GF isoform BB (PDGF-BB) between
P-PRP treated with non-ionic detergent (P-PRP+NID),
P-PRG (activated with calcium gluconate -CG-), PPP+
NID, PPP gel (PPG), and plasma and; 3) to evaluate and
to correlate the effect of the breed, gender and age on
the cellular and GF concentration for each blood
component.
The hypothesis from our study was that intrinsic fac-
tors, such as breed, gender and age could influence the
final concentration of cells and growth factors in equine
P-PRP/P-PRG.Results
General hematological results
There were statistically significant (P < 0.001) differ-
ences for all the general hematological variables evalu-
ated between whole blood, P-PRP and PPP (Figure 1A),
except MPV and PDW. Mean platelet volume values
were similar between whole blood and PPP and both
parameters differed (P < 0.001) from P-PRP. Platelet dis-
tribution width values were similar for whole blood and
P-PRP; however these PDW values differed (P < 0.001)
from same parameter in PPP (Table 1).General results for total protein, transforming growth
factor beta 1 and platelet derived growth factor isoform
BB
Total protein concentration was significantly (P < 0.001)
higher in P-PRP+NID when compared to plasma,
P-PRG, PPP+NID and, PPG. Both TGF-β1 and PDGF-
BB concentrations (either in pg/mL or pg/mg of TP)
were significantly lower for plasma in comparison with
the other blood components. P-PRP+NID and P-PRG
showed the highest significant concentrations for these
GF in comparison with plasma, PPP+NID and, PPG
(Table 2 and Figure 1B).Breed’s effect on hematological results
Platelet and WBC counts for whole blood and PPP were
statistically (P < 0.001) higher for CCH in comparison
with ACH. Lymphocyte relative count was significantly
(P < 0.001) higher in whole blood from CCH in compari-
son with ACH. GRA% was significantly (P < 0.001)
higher in whole blood and P-PRP from ACH in com-
parison with CCH. MPV values were significantly lower
in PRP for CCH in comparison with ACH and, PDW
values were significantly lower (P < 0.001) in PPP from
CCH. Pure-platelet rich plasma from CCH presented a
significant (P < 0.001) increase of RBC in comparison
with the same blood component in ACH (Table 3).Breed’s effect on total protein, transforming growth
factor beta 1 and platelet derived growth factor isoform
BB concentrations
Total protein concentrations were significantly higher
(P < 0.001) in P-PRP+NID for both breeds when com-
pared with the other blood components. In ACH, TGF-β1
and PDGF-BB (either pg/mL or pg/mg of TP) concentra-
tions were statistically (P < 0.001) higher for P-PRP+NID
and P-PRG when compared with the other blood compo-
nents. The same statistical behavior was noticed for TGF-
β1 and PDGF-BB concentrations in CCH (Table 4). When
both breeds were compared, no differences were found for
TGF-β1 concentrations between each blood component.
However, the PDGF-BB concentrations (either pg/mL or
pg/mg of TP) in CCH blood components were signifi-
cantly higher respect to ACH (Table 4).Gender’s effect on hematological results
Cellular counts, MPV and, PDW values for whole blood,
P-PRP and, PPP for each independent gender presented
a similar statistical behavior than the hematological gen-
eral results. However, PLT counts for whole blood,
P-PRP and, PPP were significantly (P < 0.001) higher in
females in comparison with males (Table 5).
Figure 1 A) Platelet (PLT) and leukocyte (WBC) concentration in whole blood, P-PRP and, PPP. B) Transforming growth factor beta 1
(TGF-β1) concentrations (pg/mL) in different plasma, P-PRP plus non ionic detergent (P-PRP+NID), pure-platelet rich gel (P-PRG), PPP+NID and
platelet poor gel (PPG) Bars represent the mean of n= 40±s.d. Different letters indicate significant differences between groups.
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factor beta 1 and platelet derived growth factor isoform
BB concentrations
Total protein, TGF-β1 and PDGF-BB (either in pg/mL or
pg/mg of TP) concentrations for each blood component
for each sex presented a same statistical behavior than
for the general results (Table 6). However, when genders
were compared, females presented significantly higher
plasma TGF-β1 (pg/mg of TP) concentrations than
males. PDGF-BB concentrations for P-PRP+NID, P-PRG
, PPP+NID and, PPG were significantly higher in females
in comparison with males (Table 6).Table 1 General results for the hematological variables of
each blood component
Variable Whole blood (n=40) P-PRP (n=40) PPP (n=40)
RBC (106/μL) 6.4 (0.7)a 0.14 (0.1)b 0.00 (0.0)
WBC (103/μL) 8.2 (1.6)a 4.3 (2.2)b 0.06 (0.0)
LY (%) 37.0 (8.6)a 58.8 (9.5)b - -
MO (%)* 1.8 (0.8)a 0.0 (1.2)b - -
EOS (%)* 3.5 (5.0)a 0.0 (3.9)b - -
GRA (%) 57.9 (9.7)a 38.4 (10.7)b - -
PLT (103/μL) 167.1 (25.9)a 304.3 (43.9)b 104.9 (25.4)
MPV (fL) 3.4 (0.4) 3.6 (1.0)a 3.3 (0.4)
PDW (%) 16.8 (0.7)b 17.1 (0.5)b 18.4 (0.7)
Data are presented as mean (±s.d.).
P-PRP: Pure-platelet rich plasma. PPP: Platelet poor plasma. RCB: Red blood
cells. WBC: White blood cells (leukocytes). LY: Lymphocytes. MO: Monocytes.
EOS: Eosinophils. GRA: Granulocytes (neutrophils and basophils). PLT: Platelets.
MPV: Mean platelet volume. PDW: Platelet distribution width. a: Significantly
different (SD) (P<0.001) from P-PRP and PPP. b: SD (P<0.001) from PPP. *Data
are presented as median (interquartile range -IR-).Age’s effect on hematological results
Cellular counts, MPV and, PDW values for whole blood,
P-PRP and, PPP for each independent age group
presented a similar statistical behavior than for the
hematological general results. Horses younger than 5
years old presented significant higher LY% and lower
GRA% than the age group of horses between 5.1-10
years old and the group of horses older than 10.1 years
old (Table 7).
Age’s effect on total protein, transforming growth factor
beta 1 and platelet derived growth factor isoform BB
concentrations
Total protein, TGF-β1 and, PDGF-BB concentrations for
each blood component for each independent age group
presented the same trend in the statistical behavior than
for the general results (Table 8). Horses younger than 5
years old presented significant lower TP concentrations
than the other age groups. The same group of horses
presented significant (P < 0.001) higher concentrations
of PDGF-BB in P-PRP+NID when compared with the
age group of horses between 5.1-10 years old and the
group of horses older than 10.1 years old. In addition, P-
PRG from the group of horses younger than 5 years old
presented higher concentrations of PDGF-BB (pg/mg of
TP) in comparison with the other age groups (Table 8).
General correlations
Significant (P < 0.001) positive correlations were detected
between PLT and PDGF-BB concentration (rs= 0.80),
PLT and TGF-β1 concentration (rs= 0.60), WBC count
and PDGF-BB concentration (rs= 0.66) and, TGF-β1
and PDGF-BB concentration (rs= 0.67). A significant
Table 2 General results for total protein, transforming growth factor beta 1 and platelet derived growth factor isoform
BB for each blood component
Variable Blood component
Plasma P-PRP+NID P-PRG PPP+NID PPG
(n=40) (n=40) (n=40) (n=40) (n=40)
Total protein -TP- (mg/mL)* 45.9 (4.4)a 49.5 (6.2)b 46.1 (4.5) 46.4 (5.0) 45.5 (5.5)
TGF-β1 (pg/mL) 1114.3 (457.7)c 3192.7 (1395.3)d 2555.5 (1069.4)d 1714.3 (496.3) 1508.0 (445.9)
TGF-β1 (pg/mg of TP) 24.4 (11.2)c 64.9 (29.5)d 56.0 (24.3)d 37.2 (11.2) 33.3 (10.5)
PDGF-BB (pg/mL) 158.1 (281.0)c 1259.7 (418.6)d 1228.8 (418.0)d 601.8 (339.3) 611.7 (295.9)
PDGF-BB (pg/mg of TP) 3.5 (6.5)c 25.5 (8.7)d 27.2 (10.8)d 13.2 (7.9) 13.6 (7.3)
Data are presented as mean (±s.d.).
P-PRG: Pure-platelet rich gel. PPG: Platelet poor gel. NID: Non ionic detergent. TGF-β1: Transforming growth factor beta 1. PDGF-BB: Platelet derived growth factor
isoform BB. Other initials like in Table 1. a: SD (P<0.001) from P-PRP+NID. b: SD (P<0.001) from P-PRG, PPP+NID and, PPG. c: SD (P<0.001) con P-PRP+NID, P-PRG,
P-PPP+NID and PPG. d: SD (P<0.001) from PPP+NID and PPG. *Data are presented as median (IR).
Giraldo et al. BMC Veterinary Research 2013, 9:29 Page 4 of 10
http://www.biomedcentral.com/1746-6148/9/29(P < 0.001) negative correlation was observed between
PDW% and PDGF-BB concentration (rs= −0.71).
Specific correlations for each blood component and the
gender sex and, age
Significant (P < 0.001) positive correlations were observed
between breed and PDGF-BB concentrations from P-PRG
(rs= 0.62), breed and PDGF-BB concentrations from PPG
(rs= 0.79).
Discussion and conclusion
Results from this study demonstrate that the double
centrifugation tube method is a reliable technique for
producing equine P-PRP, such as it was demonstrated
previously [8]. This method was initially evaluated in a
mixed group of 26 horses of different breeds, ages and,
gender [8]. In that study PLT concentration was lower
and WBC concentration was higher in P-PRP [8] in
comparison with the hematological results from ourTable 3 Hematological results for each breed and their respe
Variable
Argentinean creole horse
(n=20)
Whole blood P-PRP
RBC (106/μL)* 6.6 (0.6)a 0.0 (0.0)b† 0.0
WBC (103/μL) 7.4 (1.2)a† 4.1 (1.7)b 0.0
LY (%) 33.8 (8.9)a‡ 55.8 (8.2)b
MO (%)* 1.7 (0.8) 0.0 (0.4)
EOS (%)* 2.7 (3.9)a 0.0 (2.8)c
GRA (%) 62.4 (8.5)a‡ 42.4 (8.7)b‡
PLT (103/μL) 154.6 (23.5)a† 297.8 (39.1)b 96.2 (2
MPV (fL) 3.5 (0.4)d 3.8 (1.4)b† 3.5
PDW (%)* 17.0 (1.1)b 17.2 (0.3)b‡ 18.5
Data are presented as mean (±s.d.).
The initials like in Table 1. Letters denote SD for each independent breed in each b
PPP. c: SD (P<0.05) from PPP. d: SD (P<0.001) from P-PRP. e: SD (P<0.05) from P-PRP
between the two breeds. *Data are presented as median (IR).study. However, it was no possible to find significant dif-
ferences associated with the intrinsic variables [8] such
as was found in the present research. Thus, results from
our study (using a larger sample size of horses) suggest
that centrifugation protocols for producing equine
P-PRP and perhaps L-PRP, should be adapted in func-
tion of the breed, since possibly the size and weight of
PLT and WBC could be different for each equine specific
breed.
Some studies suggest that, cellular content will influence
the GF concentration in a determined PC [12]. This fact
was evidenced when TGF-β1 and PDGF-BB concentrations
were measured in the different blood components of our
study. However, although there are several equine studies
evaluating the GF concentration in PRP, there is conflicting
results in the TGF-β1 and PDGF-BB concentrations from
equine PG obtained by either manual methods [8,13] or
semi-automated devices [9,10,14,15]. The technique used
for GF determination and non-standardized technicalctive blood components
Colombian creole horse
(n=20)
PPP Whole blood P-PRP PPP
(0.0) 6.2 (1.0)a 0.1 (0.2)b 0.0 (0.0)
(0.0) 9.0 (1.6)a 4.4 (2.7)b 0.0 (0.0)
- - 40.2 (7.2)a 61.7 (10.1)b - -
- - 1.8 (1.2)b,e 0.0 (1.5)b - -
- - 4.3 (5.6)b 0.0 (6.2)b - -
- - 53.4 (8.9)a 34.3 (11.1)b - -
1.7)‡ 179.6 (22.2)a 310.8 (48.3)b 113.6 (26.4)
(0.4)‡ 3.3 (0.3) 3.5 (0.3)c 3.2 (0.2)
(1.0) 16.7 (0.9)b 16.8 (0.6)b 18.2 (1.0)
lood component. a: SD (P<0.001) from P-PRP and, PPP. b: SD (P<0.001) from
. †: variable SD (P<0.001) between the two breeds. ‡: variable SD (P<0.05)
Table 4 Results for total protein, transforming growth factor beta 1 and platelet derived growth factor isoform BB for
each breed and their respective blood components
Variable Blood component
Plasma P-PRP+NID P-PRG PPP+NID PPG
Argentinean Creole Horse (n=20)
Total protein -TP- (mg/mL) 47.1 (4.6) 49.4 (6.6)a 46.2 (4.0) 46.7 (3.4) 46.8 (5.6)†
TGF-β1 (pg/mL) 998.0 (521.0)b 2988.0 (1192.0)c 2644.0 (502.0)c 1508.0 (813.0) 1478.0 (876.0)
TGF-β1 (pg/mg of TP) 20.7 (10.5)d,e 60.0 (30.7)c 51.9 (14.8)c 31.2 (20.3) 32.0 (20.3)
PDGF-BB (pg/mL)* 69.9 (50.7)b† 1060.5 (279.0)c‡ 978.1 (284.7)c§ 428.7 (135.2) § 418.2 (103.0)§
PDGF-BB (pg/mg of TP)* 1.5 (1.1)a† 22.0 (7.2)c‡ 21.1 (6.9)c§ 9.2 (3.6)§ 8.8 (2.5)§
Colombian Creole Horse (n=20)
TP (mg/mL) 45.7 (5.8)f 49.6 (5.9)g,h 45.9 (5.6) 45.7 (4.7) 44.3 (4.6)
TGF-β1 (pg/mL) 1128.0 (383.0)d,e 2700.0 (2561.0)g,h 1834.0 (2220.0)d 1704.0 (884.0) 1456.0 (438.0)
TGF-β1 (pg/mg of TP) 24.5 (8.9)d,e 58.2 (42.5)d,g 42.2 (49.8)d 37.1 (16.7) 34.4 (10.9)
PDGF-BB (pg/mL)* 246.3 (378.4)b 1458.9 (445.3)c 1479.6 (381.1)c 775.0 (393.6) 805.2 (300.6)
PDGF-BB (pg/mg of TP)* 5.6 (8.8)b 29.0 (8.8)c 33.4 (10.6)c 17.1 (9.1) 18.4 (7.4)
Data are presented as median (interquartile range).
Initials like in Table 2. Letters denote significant differences (SD) for each independent breed and their respective blood component. a: SD (P<0.05) from PRG. b:
SD (P<0.003) from PRP+NID, P-PRG, PPP+NID and, PPG. c: SD (P<0.001) from PPP+NID and, PPG. d: SD (P<0.05) from PPG. e: SD (P<0.001) from PRP+NID, P-PRG
and, PPP+NID. f: SD (P<0.05) from PRP+NID. g: SD (P<0.05) from PPP+NID. h: SD (P<0.001) from PPG. †: SD (P<0.05) between breeds. ‡: SD (P<0.009) between
breeds. §: SD (P<0.001) between breeds. *Data are presented as mean (±s.d).
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findings with some of these studies.
However, our GF results could be compared with the
TGF-β1 and PDGF-BB concentrations reported by Textor
et al. [10] for equine PRP produced by a manual method
and a semi-automated device. They reported the concen-
tration for these GF in PRP+NID and compared their re-
lease from PRP activated with two collagen type I (COL1)
concentrations, 10 and 20 μg/mL [10]. In our study,
lower TGF-β1 and PDGF-BB concentrations (mean ± d.s.,
3192.7 ± 1395.3 and 1259.7 ± 418.6 pg/mL, respectively),Table 5 Hematological results for gender and their respective
Variable
Male
(n=30)
Whole blood P-PRP
RBC (106/μL) 6.5 (0.7)a 0.1 (0.1)b 0.0
WBC (103/μL) 8.0 (1.5)a 4.0 (1.8)b 0.0
LY (%) 35.9 (8.8)a 58.2 (9.9)b
MO (%)* 1.8 (0.8) 0.0 (0.9)
EOS (%)* 3.1 (3.8) 0.0 (4.0)
GRA (%) 59.6 (9.4)a 39.2 (10.4)b
PLT (103/μL) 159.7 (22.7)a† 295.7 (44.2)b‡ 99.8 (
MPV (fL) 3.4 (0.4)c 3.6 (1.1)b 3.4
PDW (%) 16.9 (0.7)b 17.1 (0.5)b 18.5
Data are presented as mean (±s.d.).
The initials like in Table 1. Letters denote SD for each independent sex in each bloo
c: SD (P<0.05) from P-PRP. d: SD (P<0.05) from PPP. †: variable SD (P<0.001) betwee
*Data are presented as median (IR).were obtained from P-PRP+NID in comparison with
equine PRP+NID (22677 ± 12125 and 4332 ± 2212 pg/
mL, respectively) reported by Textor et al. [10]. The dif-
ference observed for GF concentrations in these blood
components could be associated with a higher number of
PLT and WBC concentrated in PRP+NID from Textor
et al.’s study [10]. On the other hand, PRP activated with
COL1 produced a very lower GF release in comparison
with the TGF-β1 and PDGF-BB concentration released
from P-PRG activated with CG at 6 h. The findings of our
study suggest that CG produces a complete release of GFblood components
Female
(n=10)
PPP Whole blood P-PRP PPP
(0.0) 6.2 (0.9)a 0.1 (0.1)b 0.0 (0.0)
(0.0) 8.8 (1.7)b,c 5.2 (3.1)b 0.0 (0.0)
- - 40.5 (7.2)a 60.6 (8.6)b - -
- - 1.8 (1.5)b 0.0 (1.6)d - -
- - 5.1 (5.2)b 0.0 (3.8)d - -
- - 52.7 (9.0)b,c 35.8 (11.7)b - -
23.3)‡ 189.1 (22.7)a 329.9 (32.7)b 120.0 (26.8)
(0.4) 3.4 (0.3) 3.7 (0.2)d 3.2 (0.2)
(0.7) 16.6 (0.8)b 17.0 (0.5)b 18.2 (0.8)
d component. a: SD (P<0.001) from P-PRP and, PPP. b: SD (P<0.001) from PPP.
n males and females. ‡: variable SD (P<0.05) between males and females.
Table 6 Results for total protein, transforming growth factor beta 1 and platelet derived growth factor isoform BB for
gender and their respective blood components
Variable
Blood component
Plasma P-PRP+NID P-PRG PPP+NID PPG
Males (n=30)
TP (mg/mL)* 47.1 (4.6) 49.4 (6.6)a 46.2 (4.0)† 46.7 (3.4) 46.8 (5.6)
TGF-β1 (pg/mL) 1019.0 (467.8)b,c 3325.8 (1108.1)d 2536.6 (582.3)d 1674.8 (533.3) 1512.6 (549.7)
TGF-β1 (pg/mg of TP) 21.9 (11.6)b,c† 69.4 (28.2)d 54.9 (14.8)d 35.6 (11.1) 32.5 (13.4)
PDGF-BB (pg/mL) 69.9 (50.7)e 1060.5 (279.0)d† 978.1 (284.7)d‡ 428.7 (135.2)§ 418.2 (103.0)‡
PDGF-BB (pg/mg of TP) 1.5 (1.1)e 22.0 (7.2)d† 21.1 (6.9)d‡ 9.2 (3.6)§ 8.8 (2.5)‡
Females (n=10)
TP (mg/mL)* 45.0 (5.1) 49.5 (7.8) 43.5 (6.7) 44.3 (5.1) 42.8 (4.7)
TGF-β1 (pg/mL) 1185.6 (508.9)f 3608.0 (1906.2)c 2892.8 (1749.0) 1704.8 (504.4) 1410.0 (197.4)
TGF-β1 (pg/mg of TP) 26.7 (12.5)f 71.2 (34.8)c 64.9 (37.1) 37.9 (11.3) 32.8 (4.9)
PDGF-BB (pg/mL) 333.6 (477.8)g 1535.5 (444.6)h 1589.1 (363.7)h 864.0 (463.0) 933.7 (319.9)
PDGF-BB (pg/mg of TP) 7.7 (11.2)i 30.6 (8.0) 36.8 (10.3)h 19.4 (10.8) 21.7 (7.7)
Data are presented as mean (±s.d.).
The initials like in Table 2. Letters denote SD for each independent sex and their respective blood components. a: SD (P<0.05) from P-PRG. b: SD (P<0.001) from
P-PRP+NID, P-PRG and, PPP+NID. c: SD (P<0.05) from PPG. d: SD (P<0.001) from PPP+NID and, PPG. e: SD (P<0.001) from P-PRP+NID, P-PRG, PPP+NID and, PPG. f:
SD (P<0.05) from P-PRP+NID. g: SD (P<0.001) from P-PRP+NID and, P-PRG. h: SD (P<0.05) from PPP+NID and, PPG. i: SD (P<0.05) from P-PRP+NID, P-PRG, PPP+NID
and, PPG. †: variable SD (P<0.05) between males and females. ‡: variable SD (P<0.001) between males and females. §: variable SD (P<0.003) between males and
females. *Data are presented as median (IR).
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COL1 produced a very weak GF release from PRP [10].
Our study demonstrated that intrinsic factors such as,
breed, gender and age influence the cellular composition
of P-PRP and GF content in P-PRG. These findings are
novel and should be considered in the clinical use of these
bioproducts. However, it is important to consider that
these observations should also be confirmed for either
equine L-PRP or L-PRG obtained with semi-automated
devices using an adequate simple size of horses to avoid
unpowered studies with erroneous conclusions [16].Table 7 Hematological results for age groups and their respe
Variable
Horses younger than 5 years old Horses be
(n=7)
Whole blood P-PRP PPP Whole blood
RBC (106/μL) 6.8 (1.1)a 0.1 (0.1)b 0.0 (0.0) 6.4 (0.5)a
WBC (103/μL)* 8.0 (2.9)c 6.0 (2.4)c 0.0 (0.1) 7.5 (2.2)a
LY (%) 43.6 (5.6)a† 61.0 (7.5)c - - 38.9 (7.8)a†
MO (%)* 1.2 (1.5) 0.0 (0.0) - - 1.8 (1.3)a
EOS (%)* 4.9 (7.2)d 0.0 (0.0) - - 4.1 (5.4)
GRA (%) 49.9 (4.6)a† 36.3 (4.4)c - - 56.6 (8.8)a†
PLT (103/μL) 170.5 (21.2)b,e 327.0 (50.5)b 110.4 (32.3) 165.7 (31.2)a
MPV (fL) 3.2 (0.3) 3.0 (1.3) 3.1 (0.3) 3.5 (0.4)
PDW (%) 16.6 (1.0)b 16.7 (0.4)b 18.6 (0.9) 16.6 (0.7)a
Data are presented as mean (±s.d.).
The initials like in Table 1. Letters denote SD for each independent age group in ea
PPP. c: SD (P<0.001) from PPP. d: SD (P<0.05) from P-PRP and, PPP. e: SD (P<0.001)
10.1 years old.*Data are presented as median (IR).The most intriguing result of our study was the signifi-
cantly higher PDGF concentrations in P-PRP+NID and
P-PRG derived from CCH in comparison with ACH.
This same aspect was also observed in females in com-
parison with males and in horses younger than 5 years
old in comparison with older horses. To note, CCH is a
pony-like breed and our findings could suggest that
PDGF-BB from platelets could be a pivotal factor asso-
ciated with accelerated limb wound healing in ponies in
comparison with horses [17]. It is important to bear in
mind that anabolic GF, such as insulin like growth factorctive blood components
tween 5.1-10 years old Horses older than 10.1 years old
(n=20) (n=13)
P-PRP PPP Whole blood P-PRP PPP
0.1 (0.0)c 0.0 (0.0) 6.3 (0.8)a 0.1 (0.2)c 0.0 (0.0)
4.3 (2.1)c 0.0 (0.0) 8.3 (1.9)a 3.3 (1.5)c 0.1 (0.0)
61.1 (9.1)c - - 30.5 (7.3)a 54.0 (10.0)c - -
0.0 (1.3)b - - 1.9 (1.1) 0.0 (1.3) - -
0.0 (3.1) - - 2.5 (2.8) 0.0 (4.4) - -
36.1 (11.3)c - - 64.2 (9.5)a 42.9 (11.1)c - -
304.5 (48.1)c 103.2 (26.3) 167.4 (19.9)a 291.6 (29.1)c 104.5 (21.4)
3.8 (1.1) 3.4 (0.4) 3.4 (0.2)f 3.8 (0.3)b 3.3 (0.3)
17.1 (0.5)c 18.2 (0.6) 17.2 (0.6)c 17.3 (0.6)c 18.7 (0.7)
ch blood component. a: SD (P<0.001) from P-PRP and, PPP. b: SD (P<0.05) from
from P-PRP. f: SD (P<0.05) from P-PRP. †: SD (P<0.05) from horses older than
Table 8 Results for total protein, transforming growth factor beta 1 and platelet derived growth factor isoform BB for
age groups and their respective blood components
Variable
Blood component
Plasma P-PRP+NID P-PRG PPP+NID PPG
Horses younger than 5 years old (n=7)
TP (mg/mL) 42.0 (3.6)† 48.2 (7.1) 43.2 (5.3) 42.7 (5.5)† 41.4 (4.7)
TGF-β1 (pg/mL) 1124.0 (216.0)a 3584.0 (2044.0)b 3284.0 (2176.0) 1732.0 (844.0) 1456.0 (336.0)
TGF-β1 (pg/mg of TP) 26.8 (6.4)c 74.2 (42.6)d 72.4 (50.6)e 41.0 (16.8) 37.1 (6.9)
PDGF-BB (pg/mL) 106.7 (165.8)f,g 1417.0 (840.0)e† 1585.0 (992.7) 494.9 (864.0) 677.6 (810.6)
PDGF-BB (pg/mg of TP) 2.4 (4.1)h,i 33.2 (12.1)† 34.5 (29.0)† 12.3 (21.3) 15.1 (20.1)
Horses between 5.1-10 years old (n=20)
PT (mg/mL) 47.1 (3.9)j 50.0 (6.0)e,i 46.4 (3.9) 47.2 (5.8) 45.9 (5.6)
TGF-β1 (pg/mL) 1054.0 (633.0)f,k 2890.0 (2048.0)b 2366.0 (1044.0)k,l 1560.0 (797.0) 1456.0 (593.0)
TGF-β1 (pg/mg of TP) 22.4 (14.5)f,k 56.7 (40.4)b 49.2 (31.5)k,l 31.3 (16.6) 30.5 (15.7)
PDGF-BB (pg/mL) 72.1 (77.4)m 1180.5 (810.9)b 1140.5 (599.8)b 454.8 (353.3) 513.9 (301.9)
PDGF-BB (pg/mg of TP) 1.5 (1.3)m 25.0 (14.1)b 24.4 (12.9)b 9.8 (9.9) 11.1 (6.8)
Horses older than 10.1 years old (n=13)
TP (mg/mL) 46.7 (4.7) 49.1 (8.2) 46.9 (4.2) 46.8 (2.2) 45.8 (3.4)
TGF-β1 (pg/mL) 1012.0 (426.0)d,f 2696.0 (1678.0)b,e 2264.0 (1196.0) 1592.0 (896.0) 1520.0 (806.0)
TGF-β1 (pg/mg of TP) 22.2 (8.9)e,n 55.9 (23.4) 48.4 (16.6) 33.9 (17.6) 35.1 (11.4)
PDGF-BB (pg/mL) 59.3 (131.7)m 1007.0 (630.6)b 1208.0 (624.3)b 523.6 (207.6) 562.5 (268.6)
PDGF-BB (pg/mg of TP) 1.2 (3.0)m 21.6 (13.1)l,o 25.7 (16.4)b 10.4 (5.5) 12.8 (6.2)
Data are presented as mean (±s.d.).
The initials like in Table 2. Letters denote SD for each independent age group and their respective blood components. a: SD (P<0.05) from P-PRP+NID and, P-PRG.
b: SD (P<0.001) from PPP+NID and, PPG. c: SD (P<0.05) from the all blood components. d: SD (P<0.05) from PPP+NID and, PPG. e: SD (P<0.001) from PPG. f:
SD (P<0.001) P-PRP+NID and, P-PRG. g: SD (P<0.003) from PPP+NID and, PPG. h: SD (P<0.001) from PRP+NID. i: SD (P<0.05) from P-PRG. j: SD (P<0.05) from
P-PRP+NID. k: SD (P<0.05) from PPP+NID. l: SD (P<0.001) from PPG. m: SD (P<0.001) from the all blood components. n: SD (P<0.001) from P-PRP+NID, P-PRG and,
PPP+NID. o: SD (P<0.001) from PPP+NID. †: variable SD (P<0.05) from horses between 5.-10 years old and horses older than 10.1 years old.
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horses in comparison with older ones [18].
The main limitation of our study was associated with the
fact that only CCH females were used for gender compari-
son. However, this is the first time that significant differ-
ences between genders for PLT count in P-PRP and
PDGF-BB concentrations in P-PRG have been described
in horses. At least, two aspects could be useful to explain
these differences. First, the present study used a sample
size greater than in other equine studies [3,8-10,13]. This
situation added statistical power to the study and
increased the possibility of finding significant differences
for the evaluated variables [16]. Second, gender differences
have been reported for PLT and WBC counts in human
beings with greater concentration of these cells in females
[19]. While it is known that hormonal influences could be
associated with these hematological gender differences in
human beings [20], we did not measure the concentration
of sexual hormones in horses from our study to support
this hypothesis.
The correlation analysis from our study suggests that
PDGF-BB is one of the main GF contained in equine PLT.On the other hand, TGF-β1concentrations were associated
with both PLT and WBC counts. Of note, PDGF-BB con-
centrations were correlated with the type of breed, gender
and the age. These findings suggest that this GF should be
used as an indicator of PLT enrichment in PRP and as in-
dicator of equine PRG quality.
Taken together, our data suggests that intrinsic factors,
such as breed, sex and age can influence the cellular and
GF profile of equine P-PRP/P-PRG. Specific protocols for
concentrating platelets and GF by using manual or semi-
automated devices should be standardized in function of
the equine intrinsic factors. Additional studies are neces-
sary to know if these intrinsic factors could influence the
therapeutic potential of P-PRP/P-PRG in horses.
Methods
This study was approved by the Ethical Committee of
the Universidad de Caldas.
Horses
Forty clinically normal horses of two breeds were used.
20 animals were Argentinean Creole Horses (ACH) and,
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were geldings with a mean age of 10.7 (± 6.2) years old.
Of the CCH, 10 were mares and, 10 were geldings.
These horses had a mean age of 8.5 (± 4.1) years old.
Blood collection and preparation of the platelet
concentrates
Blood was drawn from jugular venipuncture and depos-
ited in 8.5 mL tubes with ACD solution A (ACD-A) (BD
VacutainerW, Becton Drive, Franklin Lakes, NJ, USA).
After centrifugation at 120 g for five minutes, the first
50% of the top supernatant plasma fraction, adjacent to
the buffy coat, was collected. This fraction was then
centrifuged at 240 g for five minutes and the bottom
fourth fraction was collected [8]. This fraction was con-
sidered P-PRP. The upper plasma fraction P-PRP was
considered as PPP (Figure 2). Plasma was obtained by
centrifugation of ACD-A blood at 5500 g for 8 min.
Haematological analysis
A complete automated hemogram (Celltac-α MEK 6450,
Nihon Kodhen, Japan) was performed in duplicate for
whole blood, P-PRP and, PPP. Platelet (PLT) count, mean
platelet volume (MPV fL), platelet distribution width
(PDW %), total leukocyte (WBC) count, and relative
count of neutrophils and basophils (GRA), lymphocytesFigure 2 Graphic illustrating the plasma fractions obtained from the
(50%) (FPF) obtained by the single centrifugation tube method. Right tube
plasma (PPP). BC: Buffy coat. PCV: packed cell volume.(LY), monocytes (MON), eosinophils (EOS) and, packed
cell volume (PCV) were determined.
Activation of platelet concentrates
Six hundred μL of a 10% calcium gluconate (CG) solu-
tion (9.3 mg/mL) (Ropsohn Therapeutics LtdaW, Bogotá,
Colombia) was added to 6 mL of P-PRP or PPP for pro-
ducing P-PRG and PPG, respectively. P-PRG and PPG
were incubated at 37C for 6 h to stimulate GF release.
Clots were mechanically released from the walls of the
tubes and centrifuged at 5500 g for 8 min. The resulting
supernatant was aliquoted, and frozen at −82C for later
determination of TGF-β1 and PDGF-BB.
Lysis of platelet concentrates
Samples of P-PRP and PPP were incubated at 37C dur-
ing 15 min with 600 μL of a solution containing 0.5% of
a non-ionic detergent (NID) (TritonWX100, Panreac
Química, Barcelona, Spain). Platelet concentrates treated
with NID were used as a positive control of GF release
[11]. Lysates were processed in a similar fashion than
supernatants from P-PRG and PPG.
Total protein determination
Total protein (TP) concentration from all the samples
was determined using the biuret method (Proteína totaltube-method protocol. Left tube (A) contains the first plasma fraction
(B) contains pure-platelet rich plasma (P-PRP) and platelet poor
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spectrophotometric quantification.
Determination of TGF-β1 and PDGF-BB concentration by
ELISA
The TGF-β1 and PDGF-BB concentrations from superna-
tants and lysates of each blood component were deter-
mined in duplicate by sandwich ELISA developed with
commercial antibodies for human TGF-β1 (Human TGF-
β1, DY240E, R&D Systems, Inc., Minneapolis, USA) [22]
and PDGF-BB (Human PDGF-BB, DY220, R&D Systems,
Inc., Minneapolis, USA) [23]. Both ELISA were performed
according to manufacturers’ instructions. Readings were
performed at 450 nm.
Statistical analysis
Data were analyzed using a commercial software (SPSS
18.0, IBM, Chicago, Illinois, USA). A general analysis for
comparing the cell and GF concentration between the
different hematological components was performed. The
effects of the breed (ACH and CCH), gender (male and
female) and age (horses younger than 5 years old, horses
between 5.1-10 years old and horses older than 10.1
years old) on the hematological parameters and the
TGF-β1 and PDGF-BB for the different blood compo-
nents were analyzed.
When, variables presented normal distribution
(Shaphiro-Wilk test, P > 0.05), they were presented as
means (± s.d.) and evaluated by parametric tests (i.e.
t-student test for paired samples, one way ANOVA test
and, Games-Howell test (for post-hoc paired compari-
sons). Non parametric variables (Shaphiro-Wilk test,
P<0.05) were presented as medians (interquartile range -
IR-) and, evaluated by using a Kruskal-Wallis test followed
when necessary for a U-Mann–Whitney test. Wilcoxon
test was used for non related paired comparisons. All the
variables were analyzed for general and specific correla-
tions by using a Spearman (rs) test. A P ≤ 0.05 was asset as
significant for all the tests.
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